Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COLUMN
Maurer's Healthcare Insight (44)
A Trip Down Memory LaneP. Reed MaurerThis June my eldest daughter graduated from high school, in fact the International School of the Sacred Heart where she had been enrolled since kindergarden. If you experienced this rite of passage you know…
To read the full story
COLUMN
- Why Your Brain Wants You to Stay (Even When You Want to Go)
July 31, 2026
- The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard
June 26, 2026
- More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry
May 29, 2026
- The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…